Q1 Earnings Estimate for ALNY Issued By HC Wainwright

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – HC Wainwright issued their Q1 2025 EPS estimates for shares of Alnylam Pharmaceuticals in a research note issued on Monday, February 24th. HC Wainwright analyst P. Trucchio forecasts that the biopharmaceutical company will post earnings of ($1.00) per share for the quarter. HC Wainwright has a “Buy” rating and a $500.00 price objective on the stock. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Alnylam Pharmaceuticals’ Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at $1.35 EPS, FY2025 earnings at ($1.05) EPS, FY2026 earnings at $11.93 EPS and FY2027 earnings at $26.01 EPS.

Several other brokerages also recently weighed in on ALNY. Needham & Company LLC reaffirmed a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday. Chardan Capital reaffirmed a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday. Raymond James lifted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. StockNews.com cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. Finally, Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $304.26.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $237.18 on Thursday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a market capitalization of $30.71 billion, a P/E ratio of -109.30 and a beta of 0.35. The firm’s 50 day simple moving average is $254.30 and its two-hundred day simple moving average is $262.42.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03).

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 663 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the sale, the executive vice president now directly owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Phillip A. Sharp sold 11,250 shares of the business’s stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. Insiders have sold 72,986 shares of company stock worth $20,397,849 over the last quarter. Insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $637,000. Focus Partners Advisor Solutions LLC purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $203,000. Worldquant Millennium Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 156.6% in the fourth quarter. Worldquant Millennium Advisors LLC now owns 150,191 shares of the biopharmaceutical company’s stock worth $35,341,000 after acquiring an additional 91,671 shares during the period. Zurich Insurance Group Ltd FI purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $6,583,000. Finally, Vident Advisory LLC lifted its stake in Alnylam Pharmaceuticals by 21.2% in the fourth quarter. Vident Advisory LLC now owns 1,327 shares of the biopharmaceutical company’s stock worth $312,000 after acquiring an additional 232 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.